A serious bacterial infection caused by botulinum toxin which is produced by Clostridium botulinum. Patients are infected usually by ingestion of contaminated food or wound contamination. It leads to ...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on botulism is limited primarily due to its extreme rarity, with fewer than 1 in 1,000,000 individuals affected. This rarity hampers systematic clinical studies and comprehensive documentation of clinical features. Additionally, the complexity of the condition and its potential overlap with other neurological disorders make it challenging to characterize fully.
To navigate your journey with botulism, it is essential to seek a specialist who has experience in infectious diseases or neurology, particularly those familiar with botulism and its complications. While there are no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Additionally, consider participating in clinical trials, which may offer access to cutting-edge treatments and contribute to the understanding of the condition.
Currently, there are three active clinical trials investigating various aspects of botulism. The FDA has approved the botulism antitoxin heptavalent (A, B, C, D, E, F, G) for treatment. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for botulism: https://clinicaltrials.gov/search?cond=botulism. These trials may provide insights into new treatment options and better understanding of the condition.
Actionable guidance for navigating care for botulism
To navigate your journey with botulism, it is essential to seek a specialist who has experience in infectious diseases or neurology, particularly those familiar with botulism and its complications. While there are no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Additionally, consider participating in clinical trials, which may offer access to cutting-edge treatments and contribute to the understanding of the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on botulism is limited primarily due to its extreme rarity, with fewer than 1 in 1,000,000 individuals affected. This rarity hampers systematic clinical studies and comprehensive documentation of clinical features. Additionally, the complexity of the condition and its potential overlap with other neurological disorders make it challenging to characterize fully.
To navigate your journey with botulism, it is essential to seek a specialist who has experience in infectious diseases or neurology, particularly those familiar with botulism and its complications. While there are no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Additionally, consider participating in clinical trials, which may offer access to cutting-edge treatments and contribute to the understanding of the condition.
Currently, there are three active clinical trials investigating various aspects of botulism. The FDA has approved the botulism antitoxin heptavalent (A, B, C, D, E, F, G) for treatment. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for botulism: https://clinicaltrials.gov/search?cond=botulism. These trials may provide insights into new treatment options and better understanding of the condition.
Actionable guidance for navigating care for botulism
To navigate your journey with botulism, it is essential to seek a specialist who has experience in infectious diseases or neurology, particularly those familiar with botulism and its complications. While there are no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Additionally, consider participating in clinical trials, which may offer access to cutting-edge treatments and contribute to the understanding of the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on botulism is limited primarily due to its extreme rarity, with fewer than 1 in 1,000,000 individuals affected. This rarity hampers systematic clinical studies and comprehensive documentation of clinical features. Additionally, the complexity of the condition and its potential overlap with other neurological disorders make it challenging to characterize fully.
To navigate your journey with botulism, it is essential to seek a specialist who has experience in infectious diseases or neurology, particularly those familiar with botulism and its complications. While there are no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Additionally, consider participating in clinical trials, which may offer access to cutting-edge treatments and contribute to the understanding of the condition.
Currently, there are three active clinical trials investigating various aspects of botulism. The FDA has approved the botulism antitoxin heptavalent (A, B, C, D, E, F, G) for treatment. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for botulism: https://clinicaltrials.gov/search?cond=botulism. These trials may provide insights into new treatment options and better understanding of the condition.
Actionable guidance for navigating care for botulism
To navigate your journey with botulism, it is essential to seek a specialist who has experience in infectious diseases or neurology, particularly those familiar with botulism and its complications. While there are no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Additionally, consider participating in clinical trials, which may offer access to cutting-edge treatments and contribute to the understanding of the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 7, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 3 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning botulism
Updated Dec 15, 2025
The FDA has issued a reminder to the food industry about its legal obligations for food recalls, particularly in light of a recent infant botulism outbreak linked to ByHeart infant formula. The agency is urging companies to adopt best practices to enhance recall effectiveness.
The CDC's rapid response has been crucial in addressing the first outbreak of infant botulism linked to formula, highlighting the importance of swift public health interventions. This investigation underscores the need for ongoing vigilance in food safety to protect vulnerable populations.